• Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Team Blogs
    Team Blogs Find your favorite team blogs here.
  • Login
    Login Login form

Posted by on in Uncategorized

The technical and Advisory Board (AB) meeting in Zurich took place from 11th - 12th April 2018, hosted by ETH Zurich. The first day was dedicated to consortium internal discussions. The agenda of the technical meeting was structured according to the technical work packages, aggregated by the synopsis of all work packages to bridge the networks and the work done in the past 2.5 years. We discussed a clear roadmap in terms of deliveries, task conclusions, challenges and risks for the next months until the project end. The meeting showed, that the results of collaboration within the PrECISE project are encouraging so far.



The Advisory Board members joined us on day 2: 

  • Markus Christen, UZH Digital Society Initiative & Institute of Biomedical Ethics and History of Medicine
  • Diego Di Bernardo, University of Naples and TIGEM
  • Silke Gillessen, Kantonsspital St. Gallen - Klinik für Med. Onkologie und Hämatologie
  • Hans Lehrach, Max Planck Institute for Molecular Genetics
  • Mark Rubin, University of Bern Biomedical Research Department

The discussions were fruitful for the future of the project. In particular, the Q&A session was significant in terms of new perspectives. Overall, the methods developed were positively assessed by the Advisory Board and evaluated as “cutting edge” in cancer research. The PrECISE Consortium has demonstrated to work well and the collaboration between the partners is efficient, and the integration between inputs and factors from different disciplines and tasks goes on.

Hits: 631

On Friday, 21st July 2017, the PrECISE technical and General Assembly (GA) meeting took place in Prague, Czech Republic.


The GA meeting was mainly dedicated to the ongoing periodic reporting session. The technical meeting focused on the ongoing research work of the single work packages, the upcoming challenges and the ongoing discussions between interacting partners. The discussion in WP1 and WP2 mainly focused on methods for predicting clonal compositions and evaluated them on synthetic data and on HCC profiles. The focus of the WP3 presentations was on prostatic cell line perturbation experiment time-course data processing and network reconstruction algorithms. WP4 is currently dealing with automatic reconstruction of molecular networks from publications, databases and datasets. In WP5 the focus lies on the integration of patient molecular data into the logical models - drug target prediction is one of the upcoming challenges. WP6 is currently selecting and preparing patient samples for molecular profiling. WP7 is working on the visualization of pathways and the data input interface. One of the upcoming challenges in general is taking into account a large number of factors and inputs from a variety of disciplines and tasks and integrate them in respect of the overall PrECISE goals. The meeting was great success and a lot of upcoming action points were defined.



The meeting was co-located with the 25th Conference on Intelligent Systems for Molecular Biology and the 16th European Conference on Computational Biology (ISMB/ECCB 2017). The PrECISE consortium was heavily involved in the poster sessions:

  • Session A-234: DeepGRN: Deciphering gene deregulation in cancer development using deep learning (IBM)
  • Session A-319: Inferring network statistics from high-dimensional time-course data (TUDA)
  • Session A-323: Fast biological network reconstruction from high-dimensional time-course perturbation data using sparse multivariate Gaussian processes (TUDA)
  • Session A-357: Conceptual and computational framework for logical modelling of biological networks deregulated in diseases (CI)
  • Session A-364: Pan-cancer classification of gene signatures for their information value and functional redundancy (CI)
  • Session B-276: Selection of stable biomarker signature for prediction of metabolic phenotypes (ETH, IBM)
  • Session B-330: A computational framework for systems pathology of prostate cancer (UZH, ETH, IBM)
  • Session B-384: Inferring clonal composition from multiple tumor biopsies (BCM, ETH, IBM, UZH)

The consortium is currently planning a technical meeting involving also the ADVISORY BOARD members. This meeting is planned to be held in autumn 2017.

Hits: 1353

Posted by on in Uncategorized

From 8th – 10th December the 14th Annual Rocky Mountain Bioinformatics Conference took place in Aspen. At this conference members of the International Society for Computational Biology (ISCB) meet and exchange their know-how and expertise. IBM gave a talk concerning the “Stratification of prostate cancer patients based on molecular interaction profiles” at the Rocky Conference.

Furthermore an interview with IBM on artificial intelligence was published on 2nd December 2016 in the Swiss French Newspaper L’Hebdo. For our French speaking followers, the transcript can be found here.

Members of the PrECISE consortium are currently working on submissions for the ISMB/ECCB Conference taking place from 21st until 25th July in Prague, Czech Republic. The team will also meet internally on the first day to discuss PrECISE related questions and challenges and the way forward.

Hits: 1634

Posted by on in Uncategorized

It's Movember again.


The moustache and November join up together each year to raise awareness of cancer. The Movember Foundation challenge men to change their appearance - and the face of men’s health - by growing a moustache.

Rules? Start on the 1st November clean-shaven and then grow your mo during the entire month turning it into the ribbon for men’s health.

Women? The Mo challenge is whatever you make it. Run a race. Learn to rock climb. Work out in costume. Try something new and raise funds for men's health.

Others? This Movember, get together to raise funds, make some noise and stop men dying too young.



For more information visit:

Partners of the PrECISE consortium already teamed up: COMBember



Hits: 2041

IBM's Watson is a cognitive technology that processes information more like a human than a computer. Watson can understand questions posed in natural language, searches for the appropriate terms in extensive text files, analyzes and evaluates by statistical means and finally gives the most probable answer.

It is also about the right answer when it comes to the treatment of cancer. The related questions are: Is the tumour benign or malignant? How does cancer progress? What is the effect of a certain drug?

Computer scientists from IBM are convinced that the answers can be found in the growing amount of medical diagnostic data. Cancer is of such complexity, that the recognition of typical patterns is possible only with the help of artifical intelligence.

Watch the video for more information. The clip (timeframe: 06:15 - 10:20) features the PrECISE partners Peter Wild from University of Zurich and Maria Rodriguez Martinez from IBM.

Hits: 1799
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok Decline